Another approach to target the alpha chain of the human IL‐3R (CD123) is to develop antibodies that can bind to CD123 with high affinity and can thereby inhibit the binding and the effects of IL‐3 on AML cells.64, 65. Here, IL3RA is linked to acute myeloid leukemia.